FTC urged to reinstate Opana ER pay-for-delay case against Impax
A settlement agreement between Endo Pharmaceuticals and Impax Laboratories violated the antitrust law, an attorney for the Federal Trade Commission argued Thursday, seeking to reinstate a complaint against generic drugmaker Impax...To view the full article, register now.
Already a subscriber? Click here to view full article